CU Anschutz Innovations continues to accelerate promising discoveries toward patient impact through translational science, venture development and strategic collaborations. This year’s report captures that momentum, including an ambitious effort to transform pancreatic cancer care by combining research and clinical expertise with advanced technologies from partners such as NVIDIA and Verily. Fueled by a $15 million philanthropic investment, the initiative is building an AI-powered ecosystem to uncover new insights and enable more personalized treatment.
Beyond data-driven discovery, industry partnerships are creating new pathways for CU researchers. Partnerships with Medtronic and Bayer connect CU expertise with industry capabilities to support research, drug development and emerging healthcare technologies.
That momentum extends across a growing portfolio of startups featured:
Together, these milestones illustrate the many paths innovation can take, from clinical testing and startup growth to strategic investment and acquisition.
CU Anschutz Innovations continues to grow its expertise, from strategy and ventures to licensing and legal, supported by fellows who contribute across translational science and commercialization while gaining valuable hands-on experience.
As healthcare enters a new era of possibility, CU Anschutz Innovations is connecting the people, expertise and opportunities needed to turn that potential into progress and bold ideas into meaningful impact for patients.